Carlsmed, Inc. (CARL), a Carlsbad, California-based medical technology company, develops the aprevo platform, which uses AI-enabled planning software and custom 3D-printed implants for spine fusion surgery. The stock is covered by a small group of Wall Street analysts, all of whom currently carry Buy ratings.
Five current, individually attributable targets were reviewed: BTIG at $24 (October 2026), Truist Securities at $20 (August 2026), Piper Sandler at $18 (August 2026), Needham at $17 (July 2026), and Goldman Sachs at $16 (May 2026). Their arithmetic mean is $19.00, which rounds to a $19 central target. The range is wide — from $16 to $24 — reflecting genuine disagreement about valuation and the pace of commercial adoption rather than a tightly clustered consensus.
The bullish case rests on the aprevo platform's differentiated, personalized approach to spine surgery and a steep revenue ramp. More cautious targets reflect the fact that the company remains unprofitable and is still in the early phase of commercial scale-up.
The latest verified price is approximately $16.05, near the upper end of a 52-week range of $8.50 to $17.23. Reaching $19 would require a gain of roughly 18%, a substantial move that first demands a decisive break above the $17.23 52-week high and then a push toward psychological and prior price levels around $18 and $19.
The path is underpinned by fundamentals rather than momentum alone. Trailing-twelve-month revenue of about $63 million grew roughly 65% year over year, and 2025 full-year revenue of about $50.5 million rose roughly 86% from the prior year. However, the company still posts net losses, and valuation is supported by a price-to-sales multiple rather than earnings, which keeps the path dependent on sustained top-line execution.
Several factors could support the stock. The aprevo platform addresses a large spine-surgery market with a differentiated, personalized implant approach, and the company expanded its offering with the U.S. launch of the aprevo Lumbar Bi-lateral Posterior System in October 2026. Revenue growth has been strong, and the balance sheet is solid, with roughly $89 million in cash against a modest debt load.
Analyst revisions have also been favorable. BTIG raised its target to $24 from $23, and Truist raised its target to $20 from $18, indicating improving confidence in the commercial trajectory. A healthy cash position and rising institutional attention provide additional support.
The principal risk is profitability. Carlsmed continues to generate negative net income and negative operating margins, meaning the investment case depends heavily on future growth rather than current earnings. As a commercial-stage company with a relatively small revenue base and a thin float, the stock can be volatile and sensitive to any quarterly disappointment.
Competition is another consideration: the spine-implant market is dominated by large, well-capitalized device makers with established sales channels and surgeon relationships. Slower-than-expected adoption, reimbursement or regulatory friction, or sector rotation away from unprofitable growth stocks could all weigh on valuation and delay any move toward $19.
The most important near-term level is the 52-week high of $17.23, which has acted as resistance. A sustained break above it would be the first meaningful step toward the $19 target. On the downside, the 50-day moving average near $14.9 and the 200-day moving average near $12.5 define the intermediate and longer-term trend, both sitting well below the current price and confirming an intact uptrend. Prior consolidation near the $14.5–$15 area offers a potential support zone if momentum stalls.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual assumptions vary. Investors should watch quarterly earnings and guidance — the company reported third-quarter 2026 results in November — along with revenue growth, gross margin progression, and any commentary on aprevo adoption and reimbursement. Analyst revisions, new product launches, and FDA (Food and Drug Administration) or regulatory developments are also key variables that could shift the target range.
For traders tracking short-term moves alongside longer-term analyst targets, Tickeron's AI Daily Buy/Sell Signals offer a data-driven complement. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. This helps traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual scanning allows. Explore the signals to see how AI-assisted screening can fit into your own market workflow.
The $19 central target — the average of five analyst targets spanning $16 to $24 — sits about 18% above the recent price near $16.05, making it a meaningful but not extreme objective. The case for reaching it rests on rapid revenue growth, a differentiated AI-enabled spine platform, a strong cash position, and favorable analyst revisions. The case against it rests on persistent losses, intense competition, and the fact that the stock must first clear its 52-week high. Analysts are uniformly bullish in rating, yet their targets differ widely, underscoring real uncertainty about the pace of commercialization. Whether $19 is achievable will depend primarily on continued revenue acceleration and evidence of progress toward profitability in upcoming quarterly reports.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that CARL and TEM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CARL and TEM's prices will move in lockstep.
| Ticker / NAME | Correlation To CARL | 1D Price Change % | ||
|---|---|---|---|---|
| CARL | 100% | -8.35% | ||
| TEM - CARL | 31% Poorly correlated | -4.62% | ||
| TDOC - CARL | 29% Poorly correlated | -0.45% | ||
| PRVA - CARL | 27% Poorly correlated | -0.69% | ||
| WEAV - CARL | 26% Poorly correlated | N/A | ||
| HQY - CARL | 24% Poorly correlated | +1.40% | ||
More | ||||
| Ticker / NAME | Correlation To CARL | 1D Price Change % |
|---|---|---|
| CARL | 100% | -8.35% |
| Services to the Health Industry industry (42 stocks) | 16% Poorly correlated | -0.05% |
| Health Services industry (239 stocks) | 0% Poorly correlated | -1.13% |